Cargando…

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy

Immunotherapy using monoclonal antibodies targeting the PD-1/PD-L1 interaction has shown enormous success for various cancers. Despite their encouraging results in clinics, antibody-based checkpoint inhibitors have several limitations, such as poor tumor penetration. To address these limitations of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hao, Liu, Yanli, Zhao, Zhen, Li, Yuanke, Mustafa, Bahaa, Chen, Zhijin, Barve, Ashutosh, Jain, Akshay, Yao, Xiaolan, Li, Guangfu, Cheng, Kun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013927/ https://www.ncbi.nlm.nih.gov/pubmed/35444660 http://dx.doi.org/10.3389/fimmu.2022.838966

Ejemplares similares

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
por: Liu, Hao, et al.
Publicado: (2019)

Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer
por: Zhao, Zhen, et al.
Publicado: (2019)

Discovery of Aptamer Ligands for Hepatic Stellate Cells Using SELEX
por: Chen, Zhijin, et al.
Publicado: (2017)

Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer
por: Li, Yuanke, et al.
Publicado: (2021)

Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer
por: Zhao, Zhen, et al.
Publicado: (2020)

Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis
por: Chen, Zhijin, et al.
Publicado: (2019)

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
por: Liu, Bingshan, et al.
Publicado: (2017)

PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond
por: Ishida, Yasumasa
Publicado: (2020)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy
por: Wang, Fengling, et al.
Publicado: (2021)

Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
por: Zhou, Jing, et al.
Publicado: (2021)

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
por: Cai, Jiajing, et al.
Publicado: (2019)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression
por: Zhu, Xiaodan, et al.
Publicado: (2023)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

A NOVEL IMMUNOSTIMULATORY PD-L1/OX40 TETRAVALENT BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY
por: Li, Baocun, et al.
Publicado: (2023)

Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications
por: Shin, Charles, et al.
Publicado: (2021)

Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy
por: Issafras, Hassan, et al.
Publicado: (2021)

Co‐delivery of dendritic cell vaccine and anti‐PD‐1 antibody with cryomicroneedles for combinational immunotherapy
por: Chang, Hao, et al.
Publicado: (2022)

Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
por: Peng, Xiaopeng, et al.
Publicado: (2023)

A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
por: Bian, Jin, et al.
Publicado: (2022)

Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway
por: Xu, Xinjian, et al.
Publicado: (2020)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2020)

Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer
por: Glorieux, Christophe, et al.
Publicado: (2021)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer
por: Xu, Shengjie, et al.
Publicado: (2021)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy
por: Vitale, Laura A., et al.
Publicado: (2020)

Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy
por: Yang, Qianmei, et al.
Publicado: (2020)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
por: Wei, Yuhua, et al.
Publicado: (2022)

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

The Discovery of Biomarkers in Cancer Immunotherapy
por: George, Anil P., et al.
Publicado: (2019)

Antibody light chain variable domains and their biophysically improved versions for human immunotherapy
por: Kim, Dae Young, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mlcpc9rc7hgnkv98skqb2i4pla